TTrialPathMatch Me to Trials
← Back to trials
RecruitingThrombotic MicroangiopathiesHematopoietic Stem Cell Transplantation

Efficacy and Safety Study of Narsoplimab in Pediatric Patients With High-Risk Hematopoietic Stem Cell Transplant TMA

Eligible age

0–17 yrs

Accepts

All genders

Locations

7 states

Healthy volunteers

No

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

The purpose of this study is to evaluate the safety and efficacy of narsoplimab in pediatric patients with thrombotic microangiopathies (TMA) following hematopoietic stem cell transplant (HSCT).

Sponsor: Omeros Corporation

You may qualify if…

  • ✓ 1. Age at least 28 days and less than 18 years prior to informed consent (Visit 0).
  • ✓ 2. Have informed consent from at least one parent or legal guardian as required by local law and regulation. Patient informed consent will be required if the patient has reached the local legal age of majority.
  • ✓ 3. Assent from patients as required by local law and regulation.
  • ✓ 4. Have received an allogeneic hematopoietic stem cell transplant for the treatment of benign or malignant disease.
  • ✓ 5. Have a diagnosis of HSCT-TMA defined as meeting both of the following criteria:
  • ✓ Platelet count \< 50,000/mL or a decrease in platelet count \> 50% from the highest value obtained following transplant.
  • ✓ Evidence of microangiopathic hemolysis (presence of schistocytes, serum lactate dehydrogenase \[LDH\] \> upper limit of normal (\[ULN\], or haptoglobin \< lower limit of normal \[LLN\])
  • ✓ 6. Have at least one of the following HSCT-TMA high-risk criteria:

You may not qualify if…

  • ✕ 1. All treatments for HSCT-TMA are allowed except eculizumab, ravulizumab, and defibrotide within 3 months prior to informed consent, unless failure of therapy can be documented.
  • ✕ a. Patients may not be on eculizumab, ravulizumab, or defibrotide for any indication at screening.
  • ✕ 2. Have Shiga toxin-producing Escherichia coli haemolytic uraemic syndrome (STEC-HUS). Test results obtained within 28 days prior to informed consent may be used.
  • ✕ 3. Have ADAMTS13 activity \< 10%. Test results obtained within 28 days prior to informed consent may be used.
  • ✕ 4. Have a severe, uncontrolled systemic bacterial or fungal infection requiring antimicrobial therapy, or a severe uncontrolled viral infection (as determined by the investigator); prophylactic antimicrobial therapy administered as standard of care is allowed.
  • ✕ 5. Have malignant hypertension (blood pressure \[BP\] \> 99th percentile plus 5 mmHg with bilateral hemorrhages or "cotton-wool" exudates on fundoscopic examination).
  • ✕ 6. Due to conditions other than HSCT-TMA, have a poor prognosis with a life expectancy of less than 3 months in the opinion of the Investigator.
  • ✕ 7. If pregnant or lactating.

Where it's recruiting

California

San Diego

Florida

Gainesville

Missouri

St Louis

New York

New York · Valhalla

Texas

Houston

Washington

Seattle

Source: ClinicalTrials.gov · NCT05855083 · last updated 2025-03-25